|
KMID : 0378019850280090137
|
|
New Medical Journal
1985 Volume.28 No. 9 p.137 ~ p.142
|
|
|
A Parallel Third-Party Blinded Trial of Sultamicillin and Ampicillin in the Treatment of Lower Respiratory Tract Infections in Adults
|
|
|
|
|
Abstract
|
|
|
Sultamicillin is a beta-lactamase inhibitor which in combination with ampicillin expands the spectrum to include ampiclilin-resistant organisms.
The purpose of study was to establish the safety and efficacy of sultamicillin compared to ampicillin in the treatment of lower respiratory tract infections.
A total of 60 patients with a variety of lower respiratory tract infections were treated with sultamicillin or ampicillin. The study was done by a third party blinded, parallel trial of sultamicillin administered at 750 mg every 12 hours, per os and ampicillin given as 500 mg every 6 hours, per os. All patients were treated for seven days.
Clinical efficacy was observed in 83.3% of sultamicillin group and 70% in ampicillin group. Bacteriologic efficacy was observed in 73.3% of sultamicillin group and 62.5% in ampicillin group.
Adverse effects of sultamicillin including diarrhea, nausea, and skin rash occurred in -13.3% and abnormal results of laboratory test elevation of hepatic enzyme levels occurred in 6.7% but the majority of the adverse effects disappeared, after discontinuing the medication. This finding suggests that sultamicillin is active against the beta-lactamase producing organisms.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|